Volume 24, Number 10—October 2018
Research
Candida auris in Healthcare Facilities, New York, USA, 2013–2017
Table 4
Antifungal susceptibility data for first Candida auris isolates from 51 clinical cases, New York, USA, 2013–2017*
Antifungal | Tentative resistance breakpoint (16) | MIC50† | MIC range† | No. (%) resistant |
---|---|---|---|---|
Fluconazole | >32 | >256 | 8.00 to >256 | 50 (98) |
Itraconazole | NA | 0.500 | 0.25–1.00 | NA |
Voriconazole | NA | 2.000 | 0.50–4.00 | NA |
Posaconazole | NA | 0.250 | 0.12–0.50 | NA |
Isavuconazole | NA | 0.500 | 0.25–2.00 | NA |
Caspofungin | >2 | 0.060 | 0.03–0.25 | 0 |
Micafungin | >4 | 0.120 | 0.06–0.25 | 0 |
Anidulafungin | >4 | 0.250 | 0.12–0.50 | 0 |
Amphotericin B | >2 | 1.500 | 0.50–4.00 | 15 (29) |
Flucytosine | NA | 0.125 | 0.125–0.25 | NA |
*NA, not available.
†MICs for azoles and echinocandins are defined as the lowest drug concentration that caused 50% growth inhibition compared with the drug-free controls; MICs for amphotericin B and flucytosine are defined as the lowest concentration at which there was 100% growth inhibition. MIC50 was defined as the MIC at which >50% of the isolates of C. auris tested were inhibited.
References
- Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49:3139–42. DOIPubMedGoogle Scholar
- Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013;19:1670–3. DOIPubMedGoogle Scholar
- Sarma S, Kumar N, Sharma S, Govil D, Ali T, Mehta Y, et al. Candidemia caused by amphotericin B and fluconazole resistant Candida auris. Indian J Med Microbiol. 2013;31:90–1. DOIPubMedGoogle Scholar
- Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:919–26. DOIPubMedGoogle Scholar
- Magobo RE, Corcoran C, Seetharam S, Govender NP. Candida auris-associated candidemia, South Africa. Emerg Infect Dis. 2014;20:1250–1. DOIPubMedGoogle Scholar
- Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41:285–95. DOIPubMedGoogle Scholar
- Emara M, Ahmad S, Khan Z, Joseph L, Al-Obaid I, Purohit P, et al. Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis. 2015;21:1091–2. DOIPubMedGoogle Scholar
- Calvo B, Melo ASA, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, et al. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016;73:369–74. DOIPubMedGoogle Scholar
- Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, Martínez HP, Rodríguez GJ, Álvarez-Moreno CA, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis. 2017;23:162–4. DOIPubMedGoogle Scholar
- Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35. DOIPubMedGoogle Scholar
- Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al.; MSD. MSD. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1234–7. DOIPubMedGoogle Scholar
- Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, et al. Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195–203. DOIPubMedGoogle Scholar
- Ruiz Gaitán AC, Moret A, López Hontangas JL, Molina JM, Aleixandre López AI, Cabezas AH, et al. Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. Rev Iberoam Micol. 2017;34:23–7. DOIPubMedGoogle Scholar
- Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41–4. DOIPubMedGoogle Scholar
- Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic healthcare surface. J Clin Microbiol. 2017;55:2996–3005. DOIPubMedGoogle Scholar
- Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2017;55:638–40. DOIPubMedGoogle Scholar
- Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug resistant Candida auris on 3 continents confirmed by whole genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134–40. DOIPubMedGoogle Scholar
- Centers for Disease Control and Prevention. Clinical alert to U.S. healthcare facilities—June 2016. Global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris [cited 2017 Feb 28]. https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html
- New York State Department of Health. Health advisory: alert to New York State healthcare facilities regarding the global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris [cited 2017 Nov 24]. https://www.health.ny.gov/diseases/communicable/c_auris/docs/2016-08_candida_auris_advisory.pdf
- New York State Department of Health. Health advisory: alert to New York State clinical laboratories: identification and reporting of suspected Candida auris isolates [cited 2017 Nov 24]. https://www.health.ny.gov/diseases/communicable/c_auris/docs/2016-11_candida_auris_advisory.pdf
- Stevenson LG, Drake SK, Shea YR, Zelazny AM, Murray PR. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species. J Clin Microbiol. 2010;48:3482–6. DOIPubMedGoogle Scholar
- Clinical and Laboratory Standards Institute. M27–S4 reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement. Wayne (PA): The Institute; 2012.
- Leach L, Zhu Y, Chaturvedi S. Development and validation of a real-time PCR assay for rapid detection of Candida auris from surveillance samples. J Clin Microbiol. 2018;56:e01223–17.PubMedGoogle Scholar
- Tsay S, Welsh RM, Adams EH, Chow NA, Gade L, Berkow EL, et al.; MSD. Notes from the field: ongoing transmission of Candida auris in health care facilities—United States, June 2016–May 2017. MMWR Morb Mortal Wkly Rep. 2017;66:514–5. DOIPubMedGoogle Scholar
- Okinda N, Kagotho E, Castanheira M, Njuguna A, Omuse G, Makau P, et al. Candidemia at a referral hospital in sub-Saharan Africa: emergence of Candida auris as a major pathogen. Poster presented at: European Congress of Clinical Microbiology and Infectious Diseases; 2014 May 10–13; Barcelona, Spain.
- New York State Department of Health. Get the facts about Candida auris [cited 2017 Dec 28]. https://www.health.ny.gov/diseases/communicable/c_auris/
1Additional members of the workgroup are listed at the end of this article.